SCHEMBL93996

SCHEMBL93996

CCCCCCNC(=O)CCC(=O)O

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CASP2 P42575 1/20 0.74
NAAA Q02083 1/20 0.69
EPHX2 P34913 3/20 0.68
PLA2G2A P14555 1/20 0.61
FAAH O00519 5/20 0.59
KDM4E B2RXH2 1/20 0.58
EPHX1 P07099 2/20 0.57
CNR1 P21554 2/20 0.57
CNR2 P34972 2/20 0.57
PLA2G4A P47712 1/20 0.56
DNM1 Q05193 1/20 0.56
ALDH1A1 P00352 1/20 0.56
TSHR P16473 1/20 0.56
SLC22A6 Q4U2R8 1/20 0.56
SLC22A8 Q8TCC7 1/20 0.56
GPR84 Q9NQS5 1/20 0.56
PPARG P37231 1/20 0.56
PPARD Q03181 1/20 0.56
PPARA Q07869 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL94472 1.00 CASP2 (0.74) CASP2NAAAEPHX2PLA2G2AFAAH
SCHEMBL8337296 1.00 CASP2 (0.74) CASP2NAAAEPHX2PLA2G2AFAAH
SCHEMBL10420519 1.00 CASP2 (0.74) CASP2NAAAEPHX2PLA2G2AFAAH
SCHEMBL8356691 1.00 CASP2 (0.74) CASP2NAAAEPHX2PLA2G2AFAAH
SCHEMBL1001785 1.00 CASP2 (0.74) CASP2NAAAEPHX2PLA2G2AFAAH
SCHEMBL10422182 1.00 CASP2 (0.74) CASP2NAAAEPHX2PLA2G2AFAAH
SCHEMBL10686810 1.00 CASP2 (0.74) CASP2NAAAEPHX2PLA2G2AFAAH
SCHEMBL10767322 1.00 CASP2 (0.74) CASP2NAAAEPHX2PLA2G2AFAAH
SCHEMBL30678823 0.98 CASP2 (0.71) CASP2NAAAEPHX2PLA2G2AFAAH
SCHEMBL30835571 0.98 CASP2 (0.71) CASP2NAAAEPHX2PLA2G2AFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3468996-B1 ANTI-EGFR ANTIBODY DRUG CONJUGATES ABBVIE INC (US) 2022-05-04 EP disclosed
US-20180344859-A1 NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME ALUMEND, LLC (US) 2018-12-06 US disclosed
US-20180344858-A1 NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME ALUMEND, LLC (US) 2018-12-06 US disclosed
US-9884121-B2 Biomaterials and a method for making and using same ALUMEND, LLC (US) 2018-02-06 US disclosed
US-9855337-B2 Biomaterials and a method for making and using the same ALUMEND, LLC (US) 2018-01-02 US disclosed
US-20160175449-A1 NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME ALUMEND, LLC (US) 2016-06-23 US disclosed
US-20140128352-A1 COMPOUNDS AND METHODS FOR MODULATING MITOCHONDRIAL METABOLISM AND REACTIVE OXYGEN SPECIES PRODUCTION BUCK INSTITUTE FOR RESEARCH ON AGING (US) 2014-05-08 US disclosed
EP-2114370-B1 NOVEL BIOMATERIALS FOR OCULAR DRUG DELIVERY AND A METHOD FOR MAKING AND USING SAME ALLERGAN INC (US) 2012-10-03 EP disclosed
US-8252771-B2 A modified chitosan and a prostaglandin, prostamide, non-steroidal anti-inflammatory drug, or a corticosteroid; opthalmic drug delivery solution; improved bioavailability ALLERGAN, INC. (US) 2012-08-28 US disclosed
EP-2425816-A2 A pharmaceutical composition for use in treating an ocular disease or condition and a method for producing the composition Allergan, Inc. (US) 2012-03-07 EP disclosed
EP-2114370-A2 NOVEL BIOMATERIALS FOR OCULAR DRUG DELIVERY AND A METHOD FOR MAKING AND USING SAME Allergan, Inc. (US) 2009-11-11 EP disclosed
US-7442558-B2 Phthalamide-lanthanide complexes for use as luminescent markers THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-10-28 US disclosed
US-20080207561-A1 NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME ALLERGAN, INC. 2008-08-28 US disclosed
US-20080200948-A1 NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME PHOTOBIOMED CORPORATION (US) 2008-08-21 US disclosed
WO-2008094659-A2 NOVEL BIOMATERIALS FOR OCULAR DRUG DELIVERY AND A METHOD FOR MAKING AND USING SAME ALLERGAN, INC. (US) 2008-08-07 WO disclosed
WO-2008094675-A2 NOVEL BIOMATERIALS AND METHODS FOR MAKING AND USING SAME PHOTOBIOMED CORPORATION (US) 2008-08-07 WO disclosed
US-4921942-A Organometallic compounds STEPAN COMPANY (US) 1990-05-01 US disclosed
US-4724174-A AMIDO CARBOXYL SOAPS; FILM-FORMING; SUBSTANTIVITY STEPAN COMPANY (US) 1988-02-09 US disclosed
US-4675422-A ALUMINUM COATINGS STEPAN COMPANY (US) 1987-06-23 US disclosed
EP-0220934-A2 Aluminium carboxylates STEPAN COMPANY (US) 1987-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200948-A1 NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME MMP1, PLOD3, MMP2 CASP2 3112/4885NAAA 388/4885EPHX2 428/4885
US-20140128352-A1 COMPOUNDS AND METHODS FOR MODULATING MITOCHONDRIAL METABOLISM AND REACTIVE OXYGEN SPECIES PRODUCTION PC, PCK2, TXNRD2 CASP2 963/4885NAAA 2022/4885EPHX2 3509/4885
US-20180344859-A1 NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME MMP1, PLOD3, MMP2 CASP2 3112/4885NAAA 388/4885EPHX2 428/4885
US-20180344858-A1 NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME MMP1, PLOD3, MMP2 CASP2 3112/4885NAAA 388/4885EPHX2 428/4885
US-20160175449-A1 NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME MMP1, PLOD3, MMP2 CASP2 3112/4885NAAA 388/4885EPHX2 428/4885
US-20080207561-A1 NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME PTGES, PTGES2, PTGIS CASP2 1230/4885NAAA 809/4885EPHX2 193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.